ATE365737T1 - Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren - Google Patents

Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren

Info

Publication number: ATE365737T1
Authority: AT; Austria
Prior art keywords: fatty acid; acid oxidation; oxidation inhibitors; substituted piperazine; piperazine compounds
Prior art date: 2002-12-05

Application number

AT03812835T

Other languages

English (en)

Inventor

Elfatih Elzein

Dmitry Koltun

Jeff Zablocki

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-05

Filing date

2003-12-05

Publication date

2007-07-15

2003-12-05 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE365737T1 publication Critical patent/ATE365737T1/de

Links

GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 title 1
229930195729 fatty acid Natural products 0.000 title 1
239000000194 fatty acid Substances 0.000 title 1
150000004665 fatty acids Chemical class 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000003647 oxidation Effects 0.000 title 1
238000007254 oxidation reaction Methods 0.000 title 1
206010002383 Angina Pectoris Diseases 0.000 abstract 2
206010002388 Angina unstable Diseases 0.000 abstract 1
206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010022562 Intermittent claudication Diseases 0.000 abstract 1
208000007718 Stable Angina Diseases 0.000 abstract 1
208000007814 Unstable Angina Diseases 0.000 abstract 1
206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
230000001746 atrial effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Lubricants (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT03812835T 2002-12-05 2003-12-05 Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren ATE365737T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US43150602P	2002-12-05	2002-12-05

Publications (1)

Publication Number	Publication Date
ATE365737T1 true ATE365737T1 (de)	2007-07-15

Family

ID=32507739

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03812835T ATE365737T1 (de)	2002-12-05	2003-12-05	Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren

Country Status (11)

Country	Link
US (2)	US7125876B2 (de)
EP (1)	EP1567525B1 (de)
JP (1)	JP2006510670A (de)
KR (1)	KR20050084182A (de)
AT (1)	ATE365737T1 (de)
AU (1)	AU2003300827B2 (de)
CA (1)	CA2508608A1 (de)
DE (2)	DE60328545D1 (de)
ES (2)	ES2327873T3 (de)
NZ (1)	NZ540548A (de)
WO (1)	WO2004052887A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ541069A (en) *	2003-01-03	2008-09-26	Cv Therapeutics Inc	Piperazine derivatives as fatty acid oxidation inhibitors
US7271169B2 (en) *	2004-09-08	2007-09-18	Cv Therapeutics, Inc.	Substituted heterocyclic compounds
WO2007079003A2 (en) *	2005-12-29	2007-07-12	Bayer Schering Pharma Aktiengesellschaft	Amide inhibitors of leukotriene a4 hydrolase
KR101476379B1 (ko) *	2011-11-30	2014-12-29	한국과학기술연구원	페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2267104A1 (en) *	1974-04-12	1975-11-07	Ferlux Labo Sa	Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
US4766125A (en)	1981-06-23	1988-08-23	Janssen Pharmaceutica N.V.	N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4567264A (en)	1983-05-18	1986-01-28	Syntex (U.S.A.) Inc.	Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US4558129A (en)	1983-05-18	1985-12-10	Syntex (U.S.A.) Inc.	Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4588129A (en) *	1983-09-06	1986-05-13	Hudson Oxygen Therapy Sales Company	Nebulizer
US4788306A (en) *	1987-04-03	1988-11-29	American Home Products Corporation	Fluorooxirane carboxylates as hypoglycemic agents
JPH0730456Y2 (ja)	1989-05-11	1995-07-12	株式会社神戸製鋼所	ホイールクレーンのステアリング制御装置
ES2177601T3 (es)	1989-06-23	2002-12-16	Syntex Llc	Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
JPH03141258A (ja)	1989-10-25	1991-06-17	Kowa Co	新規なピペラジン誘導体
US5455045A (en)	1993-05-13	1995-10-03	Syntex (U.S.A.) Inc.	High dose formulations
HUP0002294A3 (en) *	1997-05-26	2001-10-29	Kowa Co	Cyclic diamine compounds and medicines containing the same
NZ520780A (en) *	2000-02-18	2006-04-28	Cv Therapeutics Inc	Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2001062711A2 (en) *	2000-02-22	2001-08-30	Cv Therapeutics, Inc.	Substituted alkylene diamine compounds
US6677336B2 (en)	2000-02-22	2004-01-13	Cv Therapeutics, Inc.	Substituted piperazine compounds
AU2001238590A1 (en)	2000-02-22	2001-09-03	Cv Therapeutics, Inc.	Substituted piperazine compounds
NZ520782A (en) *	2000-02-22	2004-03-26	Cv Therapeutics Inc	Substituted piperazine compounds that are partial fatty acid oxidation inhibitors
US6451798B2 (en)	2000-02-22	2002-09-17	Cv Therapeutics, Inc.	Substituted alkyl piperazine derivatives
US6552023B2 (en)	2000-02-22	2003-04-22	Cv Therapeutics, Inc.	Aralkyl substituted piperazine compounds
US6693099B2 (en) *	2000-10-17	2004-02-17	The Procter & Gamble Company	Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
SE0003795D0 (sv) *	2000-10-20	2000-10-20	Astrazeneca Ab	Pharmaceutically useful compounds
US6573264B1 (en)	2000-10-23	2003-06-03	Cv Therapeutics, Inc.	Heteroaryl alkyl piperazine derivatives
MXPA04000565A (es) *	2001-07-19	2005-06-17	Cv Therapeutics Inc	Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos.

2003
- 2003-12-05 AT AT03812835T patent/ATE365737T1/de not_active IP Right Cessation
- 2003-12-05 WO PCT/US2003/038867 patent/WO2004052887A2/en not_active Ceased
- 2003-12-05 EP EP03812835A patent/EP1567525B1/de not_active Expired - Lifetime
- 2003-12-05 ES ES07008429T patent/ES2327873T3/es not_active Expired - Lifetime
- 2003-12-05 DE DE60328545T patent/DE60328545D1/de not_active Expired - Lifetime
- 2003-12-05 KR KR1020057010236A patent/KR20050084182A/ko not_active Ceased
- 2003-12-05 CA CA002508608A patent/CA2508608A1/en not_active Abandoned
- 2003-12-05 NZ NZ540548A patent/NZ540548A/en unknown
- 2003-12-05 DE DE60314662T patent/DE60314662T2/de not_active Expired - Lifetime
- 2003-12-05 JP JP2004559388A patent/JP2006510670A/ja active Pending
- 2003-12-05 ES ES03812835T patent/ES2287574T3/es not_active Expired - Lifetime
- 2003-12-05 AU AU2003300827A patent/AU2003300827B2/en not_active Ceased
- 2003-12-05 US US10/729,499 patent/US7125876B2/en not_active Expired - Fee Related
2006
- 2006-09-07 US US11/518,085 patent/US7407960B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2003300827A1 (en)	2004-06-30
HK1111683A1 (en)	2008-08-15
DE60314662D1 (de)	2007-08-09
DE60314662T2 (de)	2008-03-13
EP1567525A2 (de)	2005-08-31
US20040152890A1 (en)	2004-08-05
HK1083492A1 (en)	2006-07-07
US7125876B2 (en)	2006-10-24
WO2004052887A3 (en)	2004-07-15
DE60328545D1 (de)	2009-09-03
ES2327873T3 (es)	2009-11-04
CA2508608A1 (en)	2004-06-24
JP2006510670A (ja)	2006-03-30
EP1567525B1 (de)	2007-06-27
US7407960B2 (en)	2008-08-05
AU2003300827B2 (en)	2009-08-13
WO2004052887A2 (en)	2004-06-24
NZ540548A (en)	2008-03-28
KR20050084182A (ko)	2005-08-26
ES2287574T3 (es)	2007-12-16
US20070004751A1 (en)	2007-01-04

Legal Events

Date	Code	Title	Description
2007-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE292633T1 (de)	2005-04-15	Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren
NZ604478A (en)	2014-12-24	Fused heterocyclic compounds as ion channel modulators
NO20054969L (no)	2005-11-22	2-cyanopropansyreamid- og esterderivater og deres anvendelse
DE60207652D1 (de)	2006-01-05	Durch Säuregruppen disubstitierte Heteroaryl-Derivate und ihre Verwendung als Matrix Metalloproteinas Inhibitoren
ATE368656T1 (de)	2007-08-15	Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
EA200200390A1 (ru)	2002-10-31	Новые оксабиспидиновые соединения, полезные при лечении сердечных аритмий
ATE411288T1 (de)	2008-10-15	Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DE60113548D1 (de)	2006-02-02	Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
ATE440087T1 (de)	2009-09-15	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
KR960700992A (ko)	1996-02-24	페녹시페닐아세트산 유도체(Phenoxyphenylacetic acid derivatives)
NO20053627L (no)	2005-08-10	Malonamidderivater som gamma-sekretase inhibitorer
DK0949260T3 (da)	2002-09-09	Syreadditionssalte af en optisk aktiv piperidinforbindelse og fremgangsmåde til fremstilling deraf
PE20050078A1 (es)	2005-02-28	Derivados de pirrolidona como inhibidores de maob
DK1613304T3 (da)	2008-01-21	DPP-IV-inhibitorer
SE0100326D0 (sv)	2001-02-02	New compounds
MXPA02012910A (es)	2004-05-05	Amidas de acidobifenilcarboxilico, su preparacion y su uso como medicinas.
BG108941A (en)	2005-12-30	Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
NO20060314L (no)	2006-04-06	Nicotinamid-derivater anvendbare som PDE4-inhibitorer
DE60328545D1 (de)	2009-09-03	Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation
DE602004006118D1 (de)	2007-06-06	2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE60329323D1 (de)	2009-10-29	Substituierte heterozyklische verbindungen
ATE442354T1 (de)	2009-09-15	Pyrrolidinderivate als oxytocin antagonisten
WO2001062744A3 (en)	2002-02-07	Substituted piperazine compounds
WO2004067506A3 (en)	2004-11-04	Substituted heterocyclic compounds
DE60200135D1 (de)	2004-01-29	4-(2-Pyridyl)piperazine als Agonisten des 5HT7 Rezeptors